Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 1/2 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Tumor-Agnostic 1Sarcoma 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 4Neoplasms 3Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Adenocarcinoma of Lung 2Stomach Neoplasms 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1Carcinoma 1Bronchial Neoplasms 1

Interventions

pembrolizumab 90Blood Specimen Collection 41Cyclophosphamide 37Bevacizumab 36Nivolumab 35Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 23Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Docetaxel 19Oxaliplatin 18Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Ipilimumab 14Biopsy 14130-nm albumin-bound paclitaxel 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × capmatinib × 1 year × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT05722886 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
825 enrolled
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT06988475 2025-11-24

DETERMINE

Cancer Research UK

Phase 2/3 Recruiting
30 enrolled
CNSGastrointestinalOther hematologic neoplasmSarcoma

Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neuroblastoma, Sarcoma, Stomach Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡